Neoadjuvant FOLFIRINOX and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

This single-arm, phase 2 clinical trial evaluates the margin-negative resection rate in borderline-resectable pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy and individualized chemoradiotherapy.

https://ift.tt/2rhBaQz